Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemclin Diagnostics CoSHSE:688468 +2.75%72 Return-on-Tangible-Equity is 2.92% as of Mar. 2026, which is 76% below its 10-year median of 12.34. GuruFocus rates SHSE:688468 with a GF Score™ of 72/100 and a GF Value™ of ¥5.73 (Fairly Valued). The stock has 6 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Chemclin Diagnostics Co ranks better than 57.59% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Chemclin Diagnostics Co's annualized net income for the quarter that ended in Mar. 2026 was ¥35.8 Mil. Chemclin Diagnostics Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥1,226.9 Mil. Therefore, Chemclin Diagnostics Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.92%.
The historical rank and industry rank for Chemclin Diagnostics Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688468'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -88.32 Med: 12.34 Max: 21.08
Current: 3.14
During the past 9 years, Chemclin Diagnostics Co's highest Return-on-Tangible-Equity was 21.08%. The lowest was -88.32%. And the median was 12.34%.
SHSE:688468's Return-on-Tangible-Equity is ranked better than 57.59% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.14
vs SHSE:688468: 3.14
Chemclin Diagnostics Co (SHSE:688468) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chemclin Diagnostics Co Return-on-Tangible-Equity Related Terms
Chemclin Diagnostics Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Chemclin Diagnostics Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemclin Diagnostics Co Return-on-Tangible-Equity Chart
SHSE:688468 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Chemclin Diagnostics Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemclin Diagnostics Co Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chemclin Diagnostics Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chemclin Diagnostics Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.92% mean?
Chemclin Diagnostics Co (SHSE:688468) has a Return-on-Tangible-Equity of 2.92% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chemclin Diagnostics Co and its competitors. This is 76% below median its historical median of 12.34. According to the industry distribution chart, Chemclin Diagnostics Co ranks #81 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 42.4%.
Is Chemclin Diagnostics Co's Return-on-Tangible-Equity too high?
Chemclin Diagnostics Co's current Return-on-Tangible-Equity of 2.92% is 76% below median its 10-year median of 12.34. Based on the distribution chart, Chemclin Diagnostics Co ranks #81 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Chemclin Diagnostics Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemclin Diagnostics Co's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chemclin Diagnostics Co ranks #81 out of 191 companies for Return-on-Tangible-Equity. This puts Chemclin Diagnostics Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chemclin Diagnostics Co and its competitors. Chemclin Diagnostics Co's current Return-on-Tangible-Equity is 2.92%, which is 76% below median its own 10-year median of 12.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemclin Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Chemclin Diagnostics Co (SHSE:688468) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.73, compared to a current price of ¥5.98 — trading 4.4% above its estimated fair value. The current Return-on-Tangible-Equity is 2.92%, which is 76% below median its 10-year median of 12.34. Chemclin Diagnostics Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chemclin Diagnostics Co (SHSE:688468), the current Return-on-Tangible-Equity is 2.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemclin Diagnostics Co (SHSE:688468) Overvalued in 2026?
Based on GuruFocus' analysis, Chemclin Diagnostics Co stock appears to be overvalued.
The current stock price of ¥5.98 is trading 4.4% above its estimated GF Value™ of ¥5.73.
GuruFocus considers Chemclin Diagnostics Co to be Fairly Valued.
Key valuation signals for SHSE:688468:
Return-on-Tangible-Equity: 2.92% (76% below median its 10-year median of 12.34)
GF Value™: ¥5.73 vs. price of ¥5.98 (4.4% above fair value)
No single metric tells the full story. See the SHSE:688468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemclin Diagnostics Co Ltd is engaged in the development, production and sales of clinical immunochemiluminescence diagnostic testing reagents and instruments.
72GF Score
Get the complete analysis for SHSE:688468
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688468 has been successfully added to your 
